Pharmaceutical Preparations · DE · CIK 1782223
Pyxis Oncology develops novel antibody-drug conjugates targeting solid tumors, initially focusing on head and neck cancer
Comparable business profile · signals at a glance
In the 90 days to Apr 21, 2025: 1 sold $16K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 21, 2025 | Humphrey RachelDirector | Sell | 13,896 | $1.03 | $14K |
| Apr 17, 2025 | Humphrey RachelDirector | Sell | 200 | $0.97 | $194 |
| Apr 14, 2025 | Humphrey RachelDirector | Sell | 1,400 | $0.97 | $1K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.